

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Peijia Medical Limited

沛嘉醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9996)

VOLUNTARY ANNOUNCEMENT

FIRST PATIENT IMPLANT IN THE FIRST-IN-MAN CLINICAL TRIAL OF THE MonarQ TRANSCATHETER TRICUSPID VALVE REPLACEMENT SYSTEM IN THE WORLD

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Company, in partnership with inQB8 Medical Technologies, LLC (“**inQB8**”), has successfully completed the first patient implant in the first-in-man (FIM) clinical trial of the MonarQ Transcatheter Tricuspid Valve Replacement (“**TTVR**”) system (“**the System**”) in the world. The TTVR procedure was performed on November 21, 2022 at the Heart Centre, Rigshospitalet University Hospital, Copenhagen, Denmark, by interventional cardiologists Prof. Lars Søndergaard, M.D., Prof. Ole De Becker, M.D. and cardiothoracic surgeon Morten Smerup, M.D., Jacob Moller, M.D. (Echocardiographer), Hasse Moeller-Sorensen, M.D. (Anesthesiologist), along with inQB8 co-founder, executive Chairman, Chief Medical Officer, and cardiac surgeon, Arshad Quadri, M.D.

The MonarQ TTVR system is an innovative option for treating tricuspid regurgitation. The System has a unique biodynamic attachment system that utilizes and preserves the heart’s natural motion to secure the implant to the native leaflets, distribute systolic loads, and minimize paravalvular leaks over a wide range of annulus sizes.

Reference is made to the Company's announcement dated June 10, 2021. The Company entered into a strategic partnership with inQB8 and agreed to acquire the MonarQ TTVR technology, which inQB8 continues to develop on the Company's behalf. The Company owns the global right of the MonarQ TTVR technology and the product developed on the basis of it. The successful completion of the first patient implant of the FIM clinical trial of the MonarQ TTVR system is a milestone for the Company to expand our global presence and innovative structural heart portfolio. The Company will continue the clinical trial in the hope of bringing a safe and effective product to more and more patients around the world.

THE COMPANY MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET THE MonarQ TTVR SYSTEM SUCCESSFULLY. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.

By order of the Board of Directors
Peijia Medical Limited
Dr. Yi Zhang
Chairman and Executive Director

Hong Kong, November 25, 2022

As of the date of this announcement, the Board comprises Dr. Yi Zhang, Mrs. Ping Ye Zhang and Ms. Hong Ye as executive Directors, Dr. Zhiyun Yu, Mr. Jifeng Guan, Mr. Fei Chen, Mr. Jun Yang as non-executive Directors, and Dr. Stephen Newman Oesterle, Mr. Robert Ralph Parks, Mr. Wai Ming Yip and Mr. Huacheng Wei as independent non-executive Directors.